Non-Cystic Fibrosis Bronchiectasis Market
The Non-Cystic Fibrosis Bronchiectasis market report provides current treatment practices, Non-Cystic Fibrosis Bronchiectasis emerging drugs, Non-Cystic Fibrosis Bronchiectasis market share of the individual therapies, current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032. Non-Cystic Fibrosis Bronchiectasis Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed Non-Cystic Fibrosis Bronchiectasis clinical trials profiles, key cross-competition, launch date along with product development activities.
Recent Developmental Activities in the Non-Cystic Fibrosis Bronchiectasis Treatment Landscape
• Insmed is currently conducting a Phase III ASPEN trial to confirm the results seen in the Phase II WILLOW trial and to support a new drug application (NDA) for brensocatib for treating adult patients with bronchiectasis. It has completed adult patient enrollment on time and the topline results are expected by 2Q of 2024. It has received Breakthrough Therapy Designation by the US FDA as well as Priority Medicines (PRIME) designation from the EMA for patients with bronchiectasis.
• Zambion is developing the drug for treating adult patients with NCFB colonized with P. aeruginosa and is currently planning on advancing its clinical development program for approval by regulatory authorities. Other companies like CSL Behring (CSL787), CHF 6333 (Chiesi Farmaceutici), Boehringer Ingelheim (BI 1291583) are also developing drugs for the treatment of NCFB.
Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approach, Treatment Practices, and Forecasted Epidemiology @ Non-Cystic Fibrosis Bronchiectasis Market Size Report- www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Non-Cystic Fibrosis Bronchiectasis Overview
NCFB is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree, leading to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are cough, sputum production, and frequent respiratory infections.
Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report
• The increase in Non-Cystic Fibrosis Bronchiectasis market size is a direct consequence of increasing awareness and increasing diagnosed prevalent population of Non-Cystic Fibrosis Bronchiectasis in the 7MM.
• According to DelveInsight estimates, in the US, females diagnosed with NCFB are higher in number than males.
• The leading Non-Cystic Fibrosis Bronchiectasis Companies include Insmed Incorporated/ AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others
• Promising Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies include HSK31858, S-1226, ARINA-1, AP-PA02, BI 1291583, CHF 6333, CSL787, Colistimethate sodium, Brensocatib, and others.
Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation in the 7MM
• Non-Cystic Fibrosis Bronchiectasis Diagnosed prevalent cases
• Non-Cystic Fibrosis Bronchiectasis Severity-specific cases
• Non-Cystic Fibrosis Bronchiectasis Gender-specific cases
Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Epidemiological Insights- www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Non-Cystic Fibrosis Bronchiectasis Treatment Market
The current treatment regime includes antibiotics, corticosteroids, bronchodilators, medication for acid suppression, active mucous agents, and measures to enhance bronchial hygiene. Significant numbers of neutrophils within the airway lumen suggest a role for anti-inflammatory therapy in this disease. Two commonly used classes of anti-inflammatories are corticosteroids and macrolides. However, it is a universal truth that no single treatment approach is appropriate for all NCFB patients.
Non-Cystic Fibrosis Bronchiectasis Market Insights
One of the major concerns in understanding the market for NCFB is that there is a paucity of evidence to validate many of the interventions used in the daily management of NCFB. No consensus guidelines are available globally or in the US and Japan. The European Respiratory Society (ERS) recently published guidelines on the management of NCFB, and clinicians are following those recommendations. However, there is a discrepancy in data from secondary sources and those in the ERS guidelines. This scarcity leads to gaps in understanding the current treatment scenario. However, certain studies help extrapolate the current scenario, where antibiotics remain the mainstay.
Learn more about the FDA-approved drugs for Non-Cystic Fibrosis Bronchiectasis @ Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers- www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Non-Cystic Fibrosis Bronchiectasis Companies- Insmed Incorporated/ AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, Haisco Pharmaceutical, and others
• Non-Cystic Fibrosis Bronchiectasis Pipeline Therapies- HSK31858, S-1226, ARINA-1, AP-PA02, BI 1291583, CHF 6333, CSL787, Colistimethate sodium, Brensocatib, and others
• Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers
• Non-Cystic Fibrosis Bronchiectasis Market Access and Reimbursement, Unmet Needs, and Emerging Drugs
Discover more about Non-Cystic Fibrosis Bronchiectasis Drugs in development @ Non-Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies- www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Non-Cystic Fibrosis Bronchiectasis (NCFB)
3. Competitive Intelligence Analysis for Non-Cystic Fibrosis Bronchiectasis (NCFB)
4. Non-Cystic Fibrosis Bronchiectasis (NCFB): Market Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis (NCFB): Disease Background and Overview
6. Patient Journey
7. Non-Cystic Fibrosis Bronchiectasis (NCFB) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Cystic Fibrosis Bronchiectasis (NCFB) Unmet Needs
10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis (NCFB) Treatment
11. Non-Cystic Fibrosis Bronchiectasis (NCFB) Marketed Products
12. Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Therapies
13. Non-Cystic Fibrosis Bronchiectasis (NCFB): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Non-Cystic Fibrosis Bronchiectasis (NCFB)
17. KOL Views
18. Non-Cystic Fibrosis Bronchiectasis Market Drivers
19. Non-Cystic Fibrosis Bronchiectasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Non-Cystic Fibrosis Bronchiectasis Market Dynamics Report- www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
[email protected]
This release was published on openPR.
